Clearside Biomedical, Inc. (CLSDQ)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2024, Clearside Biomedical, Inc. reported revenue of $1.66M, down 79.8% from the prior year. The company ran a net loss, with a net margin of -2064.4%. It held $25.13M in total assets against $63.98M in total liabilities.
Key ratios (FY2024)
-1735.7%
Operating margin
-2064.4%
Net margin
-79.8%
Revenue growth (YoY)
| Metric (FY) | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.66M | $8.23M | $1.33M | $29.57M | $7.89M | $2.17M | $30.0K | $345.0K | $520.0K | — |
| Cost of Revenue | $149.0K | $355.0K | $204.0K | $0 | — | — | — | — | — | — |
| Operating Income | -$28.88M | -$24.84M | -$30.28M | -$627.0K | -$17.93M | -$30.30M | -$82.94M | -$58.41M | -$25.20M | -$17.32M |
| Net Income | -$34.35M | -$32.48M | -$32.95M | $376.0K | -$18.21M | -$30.77M | -$82.82M | -$58.98M | -$25.88M | -$17.64M |
| EPS (Diluted) | $-0.47 | $-0.53 | $-0.55 | $0.01 | $-0.39 | $-0.81 | — | — | — | — |
| Total Assets | $25.13M | $34.02M | $51.30M | $42.90M | $19.32M | $26.78M | $44.12M | $40.49M | $84.81M | $21.05M |
| Total Liabilities | $63.98M | $49.93M | $40.70M | $4.93M | $10.56M | $15.62M | $20.50M | $19.08M | $13.15M | $10.40M |
| Shareholders' Equity | -$38.85M | -$15.91M | $10.61M | $37.98M | $8.76M | $11.16M | $23.62M | $21.41M | $71.66M | -$36.66M |
| Cash & Equivalents | $20.02M | $28.92M | $48.26M | $30.44M | $17.29M | $22.59M | $8.04M | $9.22M | $34.82M | $20.28M |
| Operating Cash Flow | -$24.70M | -$18.14M | -$13.37M | -$10.73M | -$13.12M | -$27.07M | -$79.20M | -$51.08M | -$22.71M | — |
| Capital Expenditures | $977.0K | $1.78M | $246.0K | $0 | $55.0K | $25.0K | $88.0K | $306.0K | $3.0K | $32.0K |
| Shares Outstanding | 76.58M | 62.85M | 60.64M | 59.72M | 51.86M | 44.41M | 32.12M | 25.35M | 24.57M | 2.66M |